Use of PYLARIFY® in Specific Patient Groups

Videos
Neal Shore, MD, FACS
Carolina Urologic Research Center
Myrtle Beach, SC
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.

Related Items

Subscribe to
Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or weekly e‑Newsletter.

I'd like to receive: